Suboxone Antitrust Lawsuit 2025. Indivior agreed to a $30 million antitrust class action lawsuit settlement to resolve claims that it worked with other companies to raise the cost of suboxone, a. Reyes announced that 42 states, led by wisconsin, have negotiated a nationwide $102.5 million settlement with indivior, the.
The company settled its antitrust claims for $385 million in october 2023. The company that makes the opioid addiction treatment drug suboxone has reached a $102.5 million settlement of antitrust claims with 41 states and the district of columbia.
Users Of Suboxone Have Experienced Oral Health Issues Like Dry Mouth And Tooth Decay, And Some Have Filed Lawsuits Claiming That Indivior Failed To Warn Users Of.
This lawsuit asserts that defendants violated certain state antitrust, consumer protection, and unjust enrichment laws in the united states, harming competition and causing class members to overpay for suboxone.
The Makers Of Suboxone Have Agreed To Pay $385 Million To Resolve An Antitrust Lawsuit Filed By Direct Purchasers, Who Say The Opioid Addiction Drug’s Dissolving.
Philadelphia — the company that makes the opioid addiction treatment drug suboxone has agreed to pay $102.5 million to 41 states and the district of.
The Company That Makes The Opioid Addiction Treatment Drug Suboxone Has Reached A $102.5 Million Settlement Of Antitrust Claims With 41 States And The District Of Columbia.
A federal judge approved a $385 million settlement between a group of direct purchasers and indivior.
A $30 Million Class Action Lawsuit Has Been Settled Over Antitrust Allegations That Led To Consumers And Patients Overpaying For Suboxone, Also Known As.
Philadelphia (ap) — the company that makes the opioid addiction treatment drug suboxone has agreed to pay $102.5 million to 41 states and the district.